scispace - formally typeset
Open AccessJournal ArticleDOI

The Argus II epiretinal prosthesis system allows letter and word reading and long-term function in patients with profound vision loss

Reads0
Chats0
TLDR
Multiple blind subjects fitted with the Argus II system consistently identified letters and words using the device, indicating reproducible spatial resolution, represents significant progress in the evolution of artificial sight.
Abstract
Background Retinal prosthesis systems (RPS) are a novel treatment for profound vision loss in outer retinal dystrophies. Ideal prostheses would offer stable, longterm retinal stimulation and reproducible spatial resolution in a portable form appropriate for daily life. Methods We report a prospective, internally controlled, multicentre trial of the Argus II system. Twenty-eight subjects with light perception vision received a retinal implant. Controlled, closed-group, forced-choice letter identification, and, open-choice two-, three- and fourletter word identification tests were carried out. Results The mean±SD percentage correct letter identification for 21 subjects tested were: letters L, T, E, J, F, H, I, U, 72.3±24.6% system on and 17.7±12.9% system off; letters A, Z, Q, V, N, W, O, C, D, M, 55.0 ±27.4% system on and 11.8%±10.7% system off, and letters K, R, G, X, B, Y, S, P, 51.7±28.9% system on and 15.3±7.4% system off. (p<0.001 for all groups). A subgroup of six subjects was able to consistently read letters of reduced size, the smallest measuring 0.9 cm (1.7°) at 30 cm, and four subjects correctly identify unrehearsed two-, three- and four-letter words. Average implant duration was 19.9 months. Conclusions Multiple blind subjects fitted with the Argus II system consistently identified letters and words using the device, indicating reproducible spatial resolution. This, in combination with stable, long-term function, represents significant progress in the evolution of artificial sight.

read more

Citations
More filters
Journal ArticleDOI

Wireless Power Transfer Strategies for Implantable Bioelectronics

TL;DR: This review presents the theory, link design, and challenges, along with their probable solutions for the traditional near-field resonant inductively coupled WPT, capacitively coupled short-ranged W PT, and more recently developed ultrasonic, mid-field, and far-field coupled W PT technologies for implantable applications.
Journal Article

Retinal Prosthesis

TL;DR: The recent clinical trials are reviewed and technology breakthroughs that will contribute to next generation of retinal prostheses are highlighted.
Journal ArticleDOI

The Argus II Retinal Prosthesis System

TL;DR: The Argus(®) II as discussed by the authors is the first prosthetic vision device to obtain regulatory approval in both Europe and the USA, and it has entered the commercial market as a treatment for patients with profound vision loss from end-stage outer retinal disease, predominantly retinitis pigmentosa.
Book Chapter

The Argus II Retinal Prosthesis System

Edward Bloch, +1 more
TL;DR: A sufficiently robust safety profile was demonstrated in the phase I/II clinical trial of 30 patients, and improvement of function in terms of orientation and mobility, target localisation, shape and object recognition, and reading of letters and short unrehearsed words have also been shown.
References
More filters
Journal ArticleDOI

Visual perception in a blind subject with a chronic microelectronic retinal prosthesis

TL;DR: A retinal prosthesis was permanently implanted in the eye of a completely blind test subject and the subject was able to see perceptions of light (spots) on all 16 electrodes of the array.
Journal ArticleDOI

Will retinal implants restore vision

Eberhart Zrenner
- 08 Feb 2002 - 
TL;DR: A number of research groups are developing electrical implants that can be attached directly to the retina in an attempt to restore vision to patients suffering from retinal degeneration, despite promising results in animal experiments.
Journal ArticleDOI

Visual acuities "hand motion" and "counting fingers" can be quantified with the freiburg visual acuity test.

TL;DR: The results suggest that the category CF at 30 cm can be replaced by 0.014, using ETDRS or FrACT, and one can even reproducibly quantify VA in the HM-range, yielding a mean VA of 0.02.
Journal ArticleDOI

The artificial silicon retina microchip for the treatment of vision loss from retinitis pigmentosa.

TL;DR: The observation of retinal visual improvement in areas far from the implant site suggests a possible generalized neurotrophic-type rescue effect on the damaged retina caused by the presence of the ASR.
Related Papers (5)